Aktiesnakken — September 2009
-
emea processen er langsommere med godkendelse kommer i 1. halvår 2010
-
Store muligheder for arzerra
-
mere upbeat
-
Egfr nu
-
Individuel dosering, rash satuaration tyder på rigtig dosering
-
Vi har et hard endpoint, survival
-
filing af bla på egfr i løbet af 2010
-
Ingen data endnu! Super godt
-
Hun forklarer lidt om Biobetter. De laver antistoffer med valideret molekyler
-
Roche partnerskab
-
Highlight ved asco tidligere i år og vi får pivotal study snart
-
De skylder os milestones
-
Nice potential revenuestream in the not too distant future
-
Arzerra har potentiale i RA og MS
-
Og kører VIDERE I NHL 1st line
-
Nu riuxiamab head to head preclinical data
-
Vi ser at arzerra er bedre på de kendte måder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind